<DOC>
	<DOCNO>NCT00846508</DOCNO>
	<brief_summary>This phase III study design examine low-risk , define clinical radiological parameter , stage IB-IIB cervical cancer patient treat cisplatin-based chemoradiation , recommend method today 's standard , great toxicity similar survival rate treat radiotherapy ( RT ) alone . Patients primarily treat radiotherapy protocol , without concurrent chemotherapy control arm , weekly cisplatin ( 40 mg/M2 ) 6 course study arm . This study conduct branch Chang Gung Memorial Hospital except Chia-I . Patients randomize either arm stratification risk factor . Each arm recruit 104 patient LN systemic metastasis define CT/MRI FDG-PET . The primary end point grade 3-5 late toxicity , secondary end point 1 ) recurrence free survival ; 2 ) acute toxicity treatment ; 3 ) sit recurrence ; 4 ) quality life ; 5 ) total treatment time . It expect take 5 year recruit enough case number .</brief_summary>
	<brief_title>Cisplatin Based Chemoradiation v.s Radiotherapy Cervical Cancer With Clinically Defined Good Prognosis</brief_title>
	<detailed_description>OBJECTIVES : Primary Objectives : •To examine low-risk , define clinical radiological parameter , stage IB-IIB cervical cancer patient treat cisplatin-based CCRT great toxicity similar survival rate treat RT alone . Secondary Objectives : •To conduct translational research find molecular marker associate radiosensitivity distant metastasis cervical cancer patient . 104 case arm . ( total 208 case ) Radiotherapy start within 3 week randomization . Chemotherapy : Cisplatin 40mg/M2 IV infusion weekly concurrently radiotherapy , 6 course . Investigation treatment ( patient arm ) 1. . Hematology : A complete blood count require weekly interval . 2. . Renal function : Serum creatinine require course CT. 3. . Body weight performance status : evaluate day weekly visit radiotherapy clinic . Performance status grade ECOG scale . 4. . Quality life assessment : assess EORTC-C30 &amp; CX28 scale pre-RT , 3-4 week 6-7 week RT . Investigation follow-up : When radiotherapy ( RT ) treatment complete , patient follow out-patients basis . The first visit within 2 month last RT . For patient whose tumor regress completely end RT , monthly follow-up least 3 month time complete regression recommend . After first follow-up time compete regression tumor , patient follow 3-monthly interval 2 year , 4-monthly one year , 6-monthly . Quality life assessment : assess EORTC-C30 &amp; CX28 scale 2 month , 4-5 month RT , q 6 month x 2 yearly another 2 year . Dosage modification toxicity Toxicity must record attendance chemotherapy monthly radiotherapy `` study form '' . 1. . Hematological toxicity : ANC &lt; 1500 /mm3 and/or platelet &lt; 100,000 /mm3 prior chemotherapy require one week delay treatment level reach . If parameter still requirement 1 week later , administration chemotherapy could still proceed 1000 &lt; ANC &lt; 1500 /mm3 , platelet &gt; 50,000 /mm3 reduce dose ( 25 % ) . Radiotherapy delay unless severe infection white count le 1000/mm3 2. . Renal toxicity : ) . Cisplatin : Serum creatinine &lt; 1.5 mg % ( creatinine clearance &gt; 70 ml/min ) : full dose ; 1.6-1.9 mg % ( 0.6-0.8 mg % base line , Ccr 50-70 ml/min ) : 25 % ; &gt; 2.0 mg % ( &gt; 1.2 mg % baseline 50 % decrease Ccr ) : cisplatin 3. . Neurotoxicity : Cisplatin discontinue Grade 3 neuropathy . 30 % dose decrease Grade 2 neurotoxicity ototoxicity 4. . Ototoxicity : Ototoxicity rare within 4 -6 course cisplatin , clinical significant deterioration hearing loss ( grade 3 ) note , cisplatin discontinue . The age susceptible ototoxicity . 5. . Genitourinary complication Urinary tract infection radiation cystitis may note course treatment , CT CT+RT withhold case grade 3 toxicity 6 . Gastroenterological toxicity : Acute radiation enteritis may prelude continuation delay either CT CT+RT</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Pathologically confirm squamous cell carcinoma cervix Clinical FIGO stage IBIIB Planned primarily treat RT . Age : 45 &lt; age &lt; 80 No enlarge pelvic paraaortic LN show CTMRI ( CTMRI criterion ) positive LN FDGPET study . Patients must adequate bone marrow , pulmonary , liver renal function The interval RT randomization great 6 week . Performance status Patients must sign informed consent participate study Age ≧80 &lt; =45 Documented pelvic LN extrapelvic metastasis : paraaortic LN , lung , liver LNpositive PET scan . General medical condition attitude make unsuitable cisplatin therapy . Small cell carcinoma , adenocarcinoma adenoadenosquamous carcinoma . Previous preRT chemotherapy pelvic RT</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>chemoradiation</keyword>
</DOC>